Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis

Experimental Hematology

Volumn 38, Issue 12, 2010, Pages 1178-1188

  Fishel, Melissa L ^a   Colvin, E Scott ^a   Luo, Meihua ^a   Kelley, Mark R ^a   Robertson, Kent A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; E 3330; LYASE INHIBITOR; REDOX EFFECTOR FACTOR 1; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; BENZOQUINONES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; HUMANS; LEUKEMIA, MYELOID; OXIDATION-REDUCTION; PROPIONIC ACIDS; RECEPTORS, CXCR5; RECEPTORS, RETINOIC ACID; RESPONSE ELEMENTS; TRETINOIN;

EID: 78549255520     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.08.011     Document Type: Article

References (39)

1. Sanz M.A., Grimwade D., Tallman M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
2. Montesinos P., Bergua J.M., Vellenga E., et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009, 113:775-783.
3. Tallman M.S. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007, 20:57-65.
4. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007, 6:793-810.
5. Demary K., Wong L., Liou J.S., Faller D.V., Spanjaard R.A. Redox control of retinoic acid receptor activity: a novel mechanism for retinoic acid resistance in melanoma cells. Endocrinology 2001, 142:2600-2605.
6. Bastien J., Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004, 328:1-16.
7. Robertson K.A., Hill D.P., Xu Y., et al. Down-regulation of apurinic/apyrimidinic endonuclease expression is associated with the induction of apoptosis in differentiating myeloid leukemia cells. Cell Growth Differ 1997, 8:443-449.
8. Luo M., He H., Kelley M.R., Georgiadis M. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal 2010, 12:1247-1269.
9. Tell G., Quadrifoglio F., Tiribelli C., Kelley M.R. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 2009, 11:601-620.
10. Luo M., Delaplane S., Jiang A., et al. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal 2008, 10:1853-1867.
11. Shimizu N., Sugimoto K., Tang J., et al. High-performance affinity beads for identifying drug receptors. Nat Biotechnol 2000, 18:877-881.
12. Zou G.M., Luo M.H., Reed A., Kelley M.R., Yoder M.C. Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain. Blood 2007, 109:1917-1922.
13. Hiramoto M., Shimizu N., Sugimoto K., et al. Nuclear targeted suppression of NF-kappa B activity by the novel quinone derivative E3330. J Immunol 1998, 160:810-819.
14. Mitomo K., Nakayama K., Fujimoto K., Sun X., Seki S., Yamamoto K. Two different cellular redox systems regulate the DNA-binding activity of the p50 subunit of NF-kappa B in vitro. Gene 1994, 145:197-203.
15. Dey N., De P.K., Wang M., et al. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol 2007, 27:4179-4197.
16. Mathieu J., Giraudier S., Lanotte M., Besancon F. Retinoid-induced activation of NF-kappaB in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells. Oncogene 2005, 24:7145-7155.
17. Lefebvre P. Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. Curr Drug Targets Immune Endocr Metabol Disord 2001, 1:153-164.
18. Witcher M., Ross D.T., Rousseau C., Deluca L., Miller W.H. Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. Blood 2003, 102:237-245.
19. Georgiadis M.M., Luo M., Gaur R.K., Delaplane S., Li X., Kelley M.R. Evolution of the redox function in mammalian apurinic/apyrimidinic endonuclease. Mutat Res 2008, 643:54-63.
20. Robertson K.A., Mueller L., Collins S.J. Retinoic acid receptors in myeloid leukemia: characterization of receptors in retinoic acid-resistant K-562 cells. Blood 1991, 77:340-347.
21. Preston I.R., Tang G., Tilan J.U., Hill N.S., Suzuki Y.J. Retinoids and pulmonary hypertension. Circulation 2005, 111:782-790.
22. Fishel M.L., Delaney S.M., Durtan L.J., et al. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther 2003, 2:633-640.
23. Mizuguchi Y., Wada A., Nakagawa K., Ito M., Okano T. Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60. Biol Pharm Bull 2006, 29:1803-1809.
24. Battle T.E., Levine R.A., Yen A. Retinoic acid-induced blr1 expression promotes ERK2 activation and cell differentiation in HL-60 cells. Exp Cell Res 2000, 254:287-298.
25. Battle T.E., Roberson M.S., Zhang T., Varvayanis S., Yen A. Retinoic acid-induced blr1 expression requires RARalpha, RXR, and MAPK activation and uses ERK2 but not JNK/SAPK to accelerate cell differentiation. Eur J Cell Biol 2001, 80:59-67.
26. Wang J., Yen A. A MAPK-positive feedback mechanism for BLR1 signaling propels retinoic acid-triggered differentiation and cell cycle arrest. J Biol Chem 2008, 283:4375-4386.
27. Park U.H., Han H.S., Um E., An X.H., Kim E.J., Um S.J. Redox regulation of transcriptional activity of retinoic acid receptor by thioredoxin glutathione reductase (TGR). Biochem Biophys Res Commun 2009, 390:241-246.
28. Oka S., Ago T., Kitazono T., Zablocki D., Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med 2009, 87:785-791.
29. Boonyaratanakornkit V., McGowan E., Sherman L., Mancini M.A., Cheskis B.J., Edwards D.P. The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 2007, 21:359-375.
30. Kousteni S., Bellido T., Plotkin L.I., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730.
31. Miranda M.B., Johnson D.E. Signal transduction pathways that contribute to myeloid differentiation. Leukemia 2007, 21:1363-1377.
32. Ghisletti S., Huang W., Jepsen K., et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev 2009, 23:681-693.
33. Lee S.K., Kim J.H., Lee Y.C., Cheong J., Lee J.W. Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-kappaB, and serum response factor. J Biol Chem 2000, 275:12470-12474.
34. Mathieu J., Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann N Y Acad Sci 2006, 1090:203-208.
35. Fenaux P., Chomienne C., Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001, 38:13-25.
36. Fenaux P., Chomienne C., Degos L. Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2001, 14:153-174.
37. Riccioni R., Saulle E., Militi S., et al. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia. Leukemia 2003, 17:98-113.
38. Reiterer G., Yen A. Platelet-derived growth factor receptor regulates myeloid and monocytic differentiation of HL-60 cells. Cancer Res 2007, 67:7765-7772.
39. Reiterer G., Bunaciu R.P., Smith J.L., Yen A. Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells. FEBS Lett 2008, 582:2508-2514.